Clinical Trial Update: An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States

View source ↗

Summary

This completed observational study evaluates real-world use and safety of vericiguat in US patients with chronic heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Vericiguat (vericiguat)

Snippet

Sponsor: Bayer | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Status: COMPLETED